23 results about "A Antibody" patented technology

The present invention includes a method and kit for method for detecting anti-Ro antibody negative Sjögren's syndrome / Sjögren's disease without performing a lip biopsy comprising: obtaining a biological sample from a patient suspected of having an anti-Ro antibody negative Sjögren's syndrome / Sjögren's disease; and detecting if the biological sample has autoantibodies to at least one of: Geminin DNA Replication Inhibitor (GMNN), Kelch Domain Containing 8 A (KLHDC8A), Microtubule Associated Protein RP / EB Family Member 1 (MAPRE1), Nucleoporin 50 (NUP50), or SKI Like Proto-Oncogene (SKIL).

Provided in the present disclosure are a multi-specific antibody or antigen-binding fragment, a composition, a preparation method and the use. By means of comprehensively considering interfacial amino acid interactions, amino acid pair mutations are introduced into CH1 and CL domains of a antibody, thereby improving correct pairing between a heavy chain and a light chain in the multi-specific antibody or antigen-binding fragment.

The present application relates to a fusion protein and its application in detection of Helicobacter pylori CagA antibody, and belongs to the technical field of biology.The present application provides a fusion protein, wherein the fusion protein comprises a polypeptide with an amino acid sequence as shown in SEQ ID NO.1, or a derivative polypeptide with more than 80% homology with the amino acid sequence as shown in SEQ ID NO.1 and capable of being specifically combined with Helicobacter pylori CagA antibody; the fusion protein is capable of being specifically combined with Helicobacter pylori CagA antibody, and has a very high application prospect in detection of Helicobacter pylori CagA antibody.

1. The material of the article to which this design relates is synthetic resin. 2. The article to which this design relates is a set of teaching tools that can be used to learn about ABO blood types and RhD blood types. 3. Teaching tool A represents red blood cells, teaching tool B represents type A antigens, teaching tool C represents type B antigens, teaching tool D represents RhD antigens, teaching tool E represents anti-type A antibodies, teaching tool F represents anti-type B antibodies, and teaching tool G represents anti-RhD antibodies. 4. The article to which this design relates is designed to easily explain the phenomenon of red blood cells and the antigens present on their surfaces reacting with antibodies in serum. 5. Reference Figures 1 to 3 show the product in use. Reference Figure 1 shows that when type B red blood cells are reacted with a type A person, the anti-B antibodies in the type A serum and the type B red blood cells agglutinate. Reference Figure 2 shows that when type A red blood cells are reacted with a type B person, the anti-A antibodies in the type B serum and the type A red blood cells agglutinate. Reference Figure 3 shows the RhD phenomenon, where red blood cells with RhD antigens on their surface agglutinate with anti-RhD antibodies.

There is provided, inter alia, an aqueous solution comprising (i) an antibody protein; and (ii) a antibody protein stabilizing mixture of arginine, methionine, and a C3 polyol.

The invention relates to application of a scavenger receptor A antibody in preparation of a medicine for inhibiting plasmodium transmission, and belongs to the technical field of malaria prevention and treatment. Aiming at the technical problem that in the prior art, the drug resistance of plasmodium to drugs and the resistance of mosquito vector to insecticides are increasingly serious, so that the malaria propagation control effect is reduced, the invention provides a scavenger receptor A antibody which is specifically combined with a scavenger receptor A on the surface of macrophage to inhibit the phagocytic function of the scavenger receptor A, so that the control effect of malaria propagation is improved. Therefore, the proliferation of antimalarial active bacteria (such as Elizabeth, shigella sonnei or klebsiella oxytoca) in the stomach of the anopheles is promoted, and the development of plasmodium in the midgut of the anopheles is indirectly blocked. The antibody can be used alone or in combination with a Pfs25 antibody. The anopheles infection rate and the number of oocysts are remarkably reduced (for example, the infection rate is reduced from 81.7% to 6%), an eco-friendly biological control mode which is not prone to drug resistance is provided, and a new strategy is provided for malaria transmission blocking.

The application discloses a foot-and-mouth disease virus type A ELISA antibody detection kit and a preparation method and application thereof. The application determines a sequence of a foot-and-mouth disease virus type A GH loop epitope polypeptide and a non-specific combination of a foot-and-mouth disease virus type O, effectively solves the non-specific combination problem through sequence reduction, obviously reduces the detection sensitivity of the type A antibody after the reduction, further improves the detection sensitivity through a form of a multi-antigen peptide to display the polypeptide sequence. Finally, the polypeptide epitope combination, the antigen coated plate containing the polypeptide epitope combination and the ELISA antibody detection kit are determined. The total coincidence rate of the kit for detecting foot-and-mouth disease inactivated vaccine immune antibodies and negative serum is as high as 95% or more, but the positive detection rate of the kit for detecting foot-and-mouth disease synthetic peptide vaccine immune antibodies is obviously improved, and the cross reaction of the kit for detecting foot-and-mouth disease virus type O vaccine and pig foot-and-mouth disease virus type O inactivated vaccine immune antibodies is effectively reduced.

Provided herein are anti-PAPP-A antibodies, as well as methods of using such antibodies to treat PAPP-A-associated disorders, e.g., kidney disease.

The invention discloses a Napsin A biological fusion enzyme antibody with a signal protein tag and application, an amino acid sequence of a light chain variable region of an anti-human Napsin A antibody is shown as SEQ ID NO: 7, an amino acid sequence of a heavy chain variable region of the anti-human Napsin A antibody is shown as SEQ ID NO: 3, the signal protein tag HRP is inserted into the N end of a light chain of the anti-human Napsin A antibody, and the amino acid sequence of the light chain variable region of the obtained HRP-Napsin A antibody is shown as SEQ ID NO: 5. In addition, the invention also provides a preparation method of the HRP-Napsin A antibody, the HRP-Napsin A antibody is a molecule completely secreted along with the antibody, has no heterogeneity, is good in sensitivity, high in specificity and stable in performance, and does not need to add a secondary antibody during detection, so that the cost is saved, and the efficiency is improved.

To provide novel human-derived monoclonal neutralizing Nogo-A specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto; and to provide polynucleotides, vectors, host cells and kits related to the Nogo-A specific antibodies.SOLUTION: Provided is a human-derived recombinant monoclonal anti-Nogo-A antibody or antigen-binding fragment thereof, the antibody or antigen-binding fragment thereof binding to the Nogo-A-Δ20 domain and being capable of inducing dose-dependent neurite outgrowth and / or angiogenesis in stroke penumbra.SELECTED DRAWING: None

Provided are compositions comprising an anti-TNFα antibody sialylated with one or more N-acetylneuraminic acid molecules, and associated methods. In some embodiments, provided are methods for treating or preventing sarcoidosis and / or granuloma size or formation in patients in need thereof.

The present disclosure provides methods for treating neurological disorders (e.g., trauma of peripheral nervous system (PNS) or central nervous system (CNS)) using anti- Nogo-A antibodies or antigen-binding fragments thereof.

Provided are novel human-derived monoclonal neutralizing Nogo-A specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Polynucleotides, vectors, host cells and kits related to the Nogo-A specific antibodies are also provided. The antibodies, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for Nogo-A targeted immunotherapy and diagnosis, respectively.

The present invention relates to an anti-human interleukin-4 receptor A antibody, a pharmaceutical composition thereof or a kit, and an application thereof in the treatment of eosinophilic esophagitis.

Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of diseases and / or conditions of the skin, including hidradenitis suppurativa, atopic dermatitis, psoriasis, vitiligo, and alopecia areata, as well as other diseases and / or conditions provided herein.

The invention discloses a bispecific antibody fusion protein simultaneously targeting BMP-2 and VEGF-A. The bispecific antibody fusion protein comprises an anti-VEGF-A antibody part, the amino acid sequence of a heavy chain variable region of the anti-VEGF-A antibody part is shown as SEQ ID NO: 6, and the amino acid sequence of a light chain variable region of the anti-VEGF-A antibody part is shown as SEQ ID NO: 7; the amino acid sequence of a heavy chain variable region of the anti-BMP-2 antibody part is as shown in SEQ ID NO: 8, and the amino acid sequence of a light chain variable region of the anti-BMP-2 antibody part is as shown in SEQ ID NO: 9; the amino acid sequence of the Fc fragment is as shown in SEQ ID NO: 10. The invention also discloses a nucleic acid molecule for coding the bispecific antibody fusion protein, and application of the bispecific antibody fusion protein in preparation of drugs for treating diabetic retinopathy. According to the bispecific antibody fusion protein disclosed by the invention, by simultaneously targeting two key targets, namely VEGF-A and BMP-2, the effusion elimination rate is remarkably increased, the fibrosis area is reduced, the retinal leakage area is reduced, and the pericyte loss rate is reduced, so that the effect of treating diabetic retinopathy is improved.

This invention discloses a composite material based on hollow mesoporous carbon spheres loaded with ABO blood group monoclonal antibodies, comprising hollow mesoporous carbon spheres and ABO blood group monoclonal antibodies loaded on the hollow mesoporous carbon spheres, wherein the ABO blood group monoclonal antibodies are selected from at least one of type A antibodies and type B antibodies. This invention also discloses a method for preparing the composite material, comprising: modifying the surface of the hollow mesoporous carbon spheres with amino groups; dispersing the spheres in an ABO blood group monoclonal antibody solution; and stirring the reaction. This invention immobilizes ABO blood group monoclonal antibodies on the surface of hollow mesoporous carbon spheres, improving the stability, specificity, and sensitivity of the antibodies, and achieving rapid and accurate ABO blood group identification. This invention also discloses a kit comprising the above-mentioned composite material, and the application of this composite material in ABO blood group detection.

Provided herein are anti-VEGF-A (vascular endothelial growth factor A) antibodies, antigen-binding fragments, and the uses thereof.

An object of the present application is to provide an anti-VEGF-A antibody and an antibody conjugate thereof.SOLUTION: Anti-VEGF-A antibodies and antibody conjugates thereof have been discovered, and it has been discovered that some embodiments of the antibodies can be conjugated to moieties such as HEMA-PC polymers, that some embodiments of the antibody conjugates can retain or enhance antibody activity, and that the antibodies and antibody conjugates can be particularly useful for the treatment of diabetic retinopathy. Furthermore, a method for conjugating polymers to proteins, e.g. antibodies such as IgG1, has been found.SELECTED DRAWING: Figure 1

The present disclosure provides pharmaceutical compositions for preventing or treating chronic pruritus of unknown origin (CPUO), the pharmaceutical compositions including an anti-IL-31 receptor A antibody as an active ingredient.

The present invention provides pulmonary surfactant protein A antibodies or antigen binding antibody fragments, kits containing these antibodies and antibody fragments, and methods of using these antibodies and antibody fragments.